Stage T4B head and neck cancer survival outcome comparisons based on treatment modality: is surgery a viable treatment option? by Kidwai, Neiha
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Stage T4B head and neck cancer
survival outcome comparisons
based on treatment modality: is
surgery a viable treatment option?
https://hdl.handle.net/2144/16169
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
STAGE T4B HEAD AND NECK CANCER SURVIVAL OUTCOME 
COMPARISONS BASED ON TREATMENT MODALITY: IS SURGERY A 
VIABLE TREATMENT OPTION? 
 
 
 
 
by 
 
 
 
 
NEIHA KIDWAI 
 
B.S., University of Connecticut, 2013 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2015  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 by 
 NEIHA KIDWAI 
 All rights reserved  
   
Approved by 
 
 
 
 
First Reader   
 Scharukh Jalisi, M.D. 
      Director, Head and Neck Oncologic Surgery and Skullbase Surgery 
   Department of Neurological Surgery (joint appointment) 
 Associate Professor of Medicine 
 
 
Second Reader   
 Gwynneth Offner, Ph.D. 
 Associate Professor of Medicine,  
  
 
 
 
  iv
STAGE T4B HEAD AND NECK CANCER SURVIVAL OUTCOME 
COMPARISONS BASED ON TREATMENT MODALITY: IS SURGERY A 
VIABLE TREATMENT OPTION? 
NEIHA KIDWAI  
ABSTRACT 
 
Importance: Advanced stage head and neck cancers are often deemed unresectable due 
to the aggressive nature of the cancer. In evaluating survival patterns of patients with 
stage IVb tumors, it is valuable to determine whether patients who undergo oncological 
surgery have favorable outcomes in order to deem surgery as a viable treatment option 
and demonstrate that these patients can survive with adequate treatment.  
Objective: To determine whether patients with stage IVb cancers who undergo 
oncological surgery have favorable survival outcomes.  
Materials and Methods: Of 320 cases reviewed of patients treated for head and neck 
cancer at Boston Medical Center between June 2009 and October 2014, 18 patients with 
stage IVb tumors were identified. Information regarding date of initial diagnosis, date and 
type of treatment, and date of death were extrapolated from medical records. Mean 
survival rates were calculated to compare survival outcomes of those who received and 
those who did not receive surgical intervention.   
Results: The mean survival rate for patients who underwent surgical intervention was 
found to be 29.5 months while those who did not receive surgical intervention had a 
  v
mean survival of 20.83 months. 
Conclusion: Cancers of the head and neck are associated with poor prognoses and are 
often deemed unresectable. Patients should be offered definitive treatment despite 
recommended palliative treatment, as, with adequate treatment, favorable survival 
outcomes are attainable.  
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INTRODUCTION 
 
 Cancer is among one of the top leading causes of death in the United States, 
projected to contribute to 589,430 deaths in the U.S in 2015 (SEER). Mortality rates 
vary by staging and locations, with later stages having poorer prognoses in 
comparison to cancers discovered in earlier stages. Head and neck cancer (HNC) 
accounts for 3% of all malignancies in the United States and 10% on a global scale 
(SEER). With the incidence in males is 3.5 times more than females, it is the eighth 
most common cancer in women, fifth in men, affecting approximately 634,000 men 
and 227,000 women annually. In 2014, 40,100 people were diagnosed with head 
and neck cancer with 11,800 reported deaths, with a rising incidence in people 
below age 40 in the United States from 3% to 6% between 1973 and 1993 
(Brockstein, 2003). Laryngeal, oral cavity, and pharyngeal cancers are reportedly 
more common in African Americas, while the highest incidence of nasopharyngeal 
cancers are Asian (SEER; Cancer, 2014; Brockstein, 2003).   
 Being such a prevalent disease in todays world, there is great interest in 
determining the most effective treatment modalities in hopes of improving the 
outcomes of those diagnosed with cancer. In this study, case reports were reviewed 
from patients diagnosed with stage T4b head and neck cancers to compare survival 
outcomes of those that underwent surgical intervention and those that did not. This 
analysis will provide information regarding the efficacy and viability of surgical 
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intervention as a treatment method for advanced stage head and neck cancers that 
are otherwise treated with less aggressive approaches for palliation.   
 
Squamous Cell Carcinomas versus Nasopharyngeal Cancers 
 
 Over 95% of head and neck cancers (HNC) are squamous cell carcinomas 
(SCC), which originate in the epithelium of the mucosal lining in the upper 
aerodigestive tract (UADT), with the remaining cancers identified as 
nasopharyngeal cancers, which have distinct etiologies from SCC’s. The three types 
of nasopharyngeal carcinomas categorized histologically by the World Health 
Organization are Type I, keratinizing squamous cell carcinoma, type II, non-
keratinizing differentiated carcinoma, and Type III, undifferentiated carcinomas. 
Nasopharyngeal carcinomas have associations with Epstein-Barr Virus (EBV) 
(Bernier, 2011).   
  
Locations/staging: 
 
 Cancer stages are typically assigned using TNM (tumor, node, metastasis) 
notation, which categorizes tumors with respect to the size (T), regional lymph node 
involvement (N), and presence or extent of metastasis (M). These aspects are 
identified and the tumor is categorized as stage I, II, III, or IV with subdivisions a-c 
(Greene, 2002).  
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 Staging for SCC’s among the various regions in the head and neck are 
relatively similar, while nasopharyngeal cancers have distinct staging from SCC’s. 
The typical staging designations for SCC’s are as follows:  
 
 TX – Primary tumor cannot be assessed  
 T0  -- No evidence of primary tumor 
 Tis – Carcinoma is in situ 
 T1 – Tumor is < or equal to 2cm 
 T2 – Tumor is > 2cm and < 4cm   
 T3—Tumor is > 4cm  
 T4 – Tumor invades adjacent structures  
  T4a- surgically resectable 
  T4b- surgically unresectable 
 NX – Regional lymph nodes cannot be assessed 
 N0—No regional nodes metastasis 
 N1— Metastasis is in a single ipsilateral lymph node, equal to or <   
3cm  
N2— Metastasis in a single ipsilateral lymph node, tumor > 3cm but 
<6cm, or metastasis in bilateral or contralateral lymph nodes 
<6cm  
 N2a – metastasis in single ipsilateral node; tumor >3cm but <6cm 
 N2b – Metastasis in multiple ipsilateral, <6cm  
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 N2c – metastasis in bilateral or contralateral lymph nodes, < 6cm  
 N3—Metastasis in lymph node > 6cm  
 MX—Distant metastasis cannot be assessed 
 M0—No distant metastasis.  
 M1 – Distant metastasis.  
 
Stage Grouping: 
Stage 0  Tis N0 M0 
Stage 1  T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
  T1 N1 M0 
  T2 N1 M0 
  T3 N1 M0 
Stage IVA T4a N0 M0 
  T4a N1 M0 
  T1        N2 M0 
  T2 N2 M0 
  T3 N2 M0 
  T4a N2 M0 
Stage IVB T4b  Any N M0 
  Any T N3 M0 
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Stage IVC Any T Any N M1 
(Deschler, 2008) 
 
Staging varies by location and is important to identify, as it dictates the course of 
treatment and is highly indicative of a patients’ prognosis (Greene, 2002). With head 
and neck cancers, early stage patient demonstrate a 60-95% chance of cure with 
local treatment and those with advanced stage cancer have greater than a 50% risk 
of recurrence or metastasis after treatment (Brockstein, 2003).  
 Head and neck cancers are divided into six regions: oral cavity, pharynx, 
larynx, nasal cavity and paranasal sinuses, and salivary glands. Tumors of the 
thyroid region are categorized as head and neck cancers but are examined 
separately due to their distinct etiology (Greene, 2002).  Each region is described 
below: 
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Figure 1: Head and Neck Cancer Regions (Figure downloaded from National Cancer 
Institute).  
 
 
Oral Cavity (and lips) 
 The oral cavity, the most common site for squamous cell cancers, includes the 
lips, anterior tongue, floor of the mouth, mandible, gums, lining of the cheeks and 
lips, and the hard palate (Brockstein, 2003). Of these subregions, SCC’s are most 
commonly found in the tongue. Due to their proximity to structures in the neck, 
tumors of the floor of the mouth spread easily throughout the head and neck regions 
(Brockstein, 2003).   
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Pharynx  
 
 The pharynx is divided into three subregions: the nasopharynx, the upper 
region, the oropharynx, where the oral cavity ends at the junction of the hard and 
soft palates, and the hypopharynx. Pharyngeal cancers also include cancers of the 
base of tongue, and soft palate. While tumors of the anterior tongue are the most 
common in the oral cavity region, base of tongue tumors are less common yet are 
typically found at later stages due to its location. The oropharynx allows airflow 
from the nose into the upper airway and closes off the oropharynx from the 
nasopharynx, preventing regurgitation of food and liquids into the nasal cavity. As 
aforementioned, nasopharyngeal cancers have distinct etiologies from squamous 
cell carcinomas. The oropharynx includes the base of the tongue and tonsils as well. 
Metastasis into the lymph nodes is common in tumors of the oropharynx. The last 
region of the pharynx is the hypopharynx, which connects the oropharynx with the 
esophagus. Hypopharyngeal tumors typically present in the late stages; by nature 
they are aggressive tumors that are discovered after metastases (Brockstein, 2003).  
 
Larynx: 
 
 The larynx, more commonly known as the voice box, is located below the 
pharynx. This region includes the vocal cords and the epiglottis, which protects the 
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airway from food aspiration. This region is separated into subsites: supraglottis, 
glottis, and subglottis . Due to the involvement of the glottis in speech, these cancers 
are found before metastases. Cancers of the subglottis are the least common cancer 
subsite of the larynx. Subglottic cancers have high mortality rates as they are often 
found in the late stages (Brockstein, 2003).   
 
Nasal Cavity 
 The nasal cavity is the hollow space inside the nose while the paranasal 
sinuses are the hollow spaces in the bones of the head surrounding the nose 
(Brockstein, 2003).   
 
Salivary Glands:  
 The salivary glands consist of the parotid, submandibular, and 
sublingual glands (Brockstein, 2003).  
 
Survival Rates 
 
Staging varies by location and is important to identify, as it dictates the 
course of treatment and is highly indicative of a patients’ prognosis (Greene, 2002). 
With head and neck cancers, early stage patient demonstrate a 60-95% chance of 
cure with local treatment and those with advanced stage cancer have greater than a 
50% risk of recurrence or metastasis after treatment (Brockstein, 2003). 
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As aforementioned, cancers in each region are distinct from one another; this 
difference can be observed by evaluation of the survival rates. Survival curves can 
display either observed survival, which expresses the percentage of patients alive 
after a certain interval of time, or relative survival, the percentage of patients that 
are alive after an interval of time relative to people without cancer. The American 
Joint Committee on Cancer provides survival analyses as such through evaluation of 
reported cases using the National Cancer Data Base, NCDB from various years.  
The AJCC relative survival curve for oral cavity expresses a 68.1% five-year 
survival rate for those with stage one cancers of the oral cavity, while stage 4 
cancers are significantly less at 26.5% from data collected from the NCDB in 1985 to 
1991 (Greene, 2002). An identical analysis run using data from 1998-1999 boast 
survival rates of 71.5% for stage one cancers and 31.9% for stage 4 (Edge & 
Compton, 2010). These differences between the older and newer reports, while 
marginal, show promise that advancement in medical technologies are bettering 
patients chances of survival. 
 The differences among regions of the head and neck are distinct from one 
another, however, there are regional differences among the subsites within the 
pharynx; this can be visualized in the survival curves in Figures 2-4 which show 
relative survival rates calculated by the AJCC using data from the NCDB from 1985-
1991.  
 Nasopharyngeal cancers boast the highest five-year survival rates with stage 
one cancers calculated at 62.5% and 38.9% for patients with stage four cancers 
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(Figure 2). The relative survival rate has shown improvement over time as the AJCC 
analyses from 1998-1999 data expresses a 71.5% five-year survival rate for stage 
one nasopharyngeal carcinomas and 38.4% for stage four cancers (Edge & Compton, 
2010). The combined AJCC stage for SCC’s of the pharynx from data collected from 
1998-1999 express five-year survival rates for stage one cancers at 35.6% and 
19.4% for stage four (Edge & Compton, 2010). 
 Stage one oropharyngeal cancers have a 57.3% survival rate for stage one 
patients and 29.6% for stage four (Figure 3), while, the worst prognoses of the 
pharyngeal regions are shown for hypopharyngeal cancers with stage one cancers 
exhibiting a 40.7% survival rate and stage four 19.9% (Figure 4). The later collected 
data from 1998-1999 shows improvement in survival for oropharyngeal cancers to 
72.6% for stage one, and 32.4% for stage four, while hypopharyngeal cancers have 
also displayed improvement with a 53% and 24.4% five-year survival rate for stage 
one and stage four hypopharyngeal cancers, respectively (Edge & Compton, 2010).  
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Figure 2: AJCC five-year relative survival for squamous cell carcinoma of the 
nasopharynx (Figure taken from Greene, 2002).  
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Figure 3: AJCC five-year relative survival for squamous cell carcinoma of the 
oropharynx (Figure taken from Greene, 2002).  
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Figure 4: AJCC five-year relative survival for squamous cell carcinoma of the 
hypopharynx (Figure taken from Greene, 2002).  
 
The plotted survival curve for laryngeal cancers exhibit a 79.9% survival rate 
for stage 1 cancers, and 36.7% for stage 4, significantly greater than the survival 
rates observed in pharyngeal cancers based on data from 1985-1991 (Greene, 
2002). Later data analyses from 1998-1999 express a relative survival rate of 84.3% 
and 35.5% for stage one and stage four laryngeal carcinomas, respectively (Edge & 
Compton, 2010).   
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The calculated AJCC five-year relative survival rates for the nasal cavity show 
a 60.4% survival rate for stage one cancers and 31.1% for patients with stage 4 
cancers (Greene, 2002).   
The five-year survival shows marked differences between stage one and 
stage four rates at 85.8% and 31.9% respectively in the salivary glands (Greene, 
2002).  
Figure 5 superimposes each subsite for comparison of survival rate by 
region. Survival rates vary by region, with lip cancers having the greatest survival 
rate after time of initial diagnoses, and hypopharyngeal cancers showing the 
shortest long-term survival after diagnoses. 
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Figure 5: Relative Survival Rate of Head and Neck Cancer patients divided by 
subsite, reported between 1988 and 2001 using SEER data (Figure taken from 
SEER).  
 
Causes/Risk Factors:  
 
 Cancer is a result of uncontrolled cell growth; these malignant 
transformations can be caused by a variety of factors. The loss of chromosomal 
region 9p21 is the most common cause. This mutation inactivates p16, a gene vital 
to cell cycle regulation. In 50% of cancers, a mutation in the p53 gene is involved 
(Brockstein, 2003).  
 While cancer can often be attributed to random genetic mutations, several 
risk factors have also been identified as causal for head and neck cancer. With over 
50 carcinogens found in tobacco such as polycyclic aromatic hydrocarbons, 
nitrosamines, and aromatic amines, unsurprisingly, it is among one of the strongest 
contributors to head and neck cancer (Cancer, 2014). The strongest correlation has 
been found between tobacco and alcohol use and head and neck cancer with 75% 
being attributable to use of these substances (Alcohol, 2007). As the two habits are 
strongly associated with each other, a study was conducted to analyze the habits of 
exclusive tobacco or alcohol users. With tobacco use, a relationship between the 
two demonstrate a dose-response relationship was found, corresponding to 
frequency and duration, while exclusive alcohol users were only found to have 
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increased risk for head and neck cancer if they drank five or more drinks per day 
(Alcohol, 2007). An association has also been shown with tobacco use and 
laryngeal cancers in particular and alcohol use with both pharyngeal and laryngeal 
cancers (Alcohol, 2007).  
 Over 5% of patients who continue to smoke experience second primary 
malignancies, SPM’s, or new cancers originated in other sites of the body after 
initial cancer, which can be attributed to the carcinogens taking their toll on other 
regions of the body. SPM’s typically present in other head and neck regions, or the 
lungs and esophagus (Brockstein, 2003). The risk of SPM has been found to show 
correlation with age as well as extent of tobacco usage (Brockstein, 2003).  
 Human papilloma virus, or HPV, a DNA virus, results in high-risk infections 
for malignant transformations as it encodes two major oncogenes (E6 and E7) 
involved in cell cycle regulation, inactivating p53 and resulting in the promotion of 
cell proliferation and growth. HPV has been associated with increased risk for 
HNC’s as 35% of those with HNC have HPV; this association is particularly seen 
between HPV and oropharyngeal cancers (Ernster et al., 2011). Similarly, Epstein-
Barr virus, EBV, has been strongly associated with nasopharyngeal carcinomas. In 
addition, poor diet and oral hygiene has been linked to head and neck cancer, 
including poor dentition, lack of toothbrush use, and not having dental check-ups 
(Guha et al., 2007). This observation is validated by the observable higher 
incidences of head and neck cancers among persons of lower socioeconomic status 
due to lack of education on proper oral hygiene and availability of resources to 
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obtain proper dentition. Two-thirds of malignancies are reported from developing 
countries where there are high consumption rates of tobacco and alcohol, and poor 
diet (Bernier, 2011). 
 
Diagnosis Techniques: 
 
 Signs and symptoms of head and neck cancer range from facial pain, 
earaches, headaches, throat pain, diplopia, and hearing deficits, to nasal 
obstructions.  These symptoms are typically subtle and can easily be missed by 
both the patient and a medical examiner; with early stage tumors often being 
asymptomatic, diagnoses are often not made until the cancer has progressed to a 
later stage (Brockstein, 2003). With diagnoses of cancer, it is also crucial to 
determine the staging as this indicates course of treatment. With thorough physical 
examination, the cancer can be assessed pending confirmation through histological 
testing. If a tumor in the oral cavity or oropharyngeal cavity is evident during 
examination, fine needle aspiration (FNA) can be used to confirm a diagnosis, while 
other unknown primary malignancies can be revealed with use of a pandendoscopy 
with random biopsies of other HNC regions (Brockstein, 2003). 
 Often endoscopic procedures are employed to better visualize the tumorous 
growth; laryngoscopy, pharyngoscopy, nasopharyngoscopy, depending on the area 
of interest. Several other region-specific tests can be employed to diagnose cancer; 
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in the case of laryngeal cancer, often barium swallow tests are a useful diagnosis 
tool.  
 Imaging tools such as ultrasound, magnetic resonance imaging (MRI), 
computed tomography (CT) scans, and positron emission tomography (PET) scans, 
are effective in confirming differential diagnoses as they can provide information 
about extent of the cancers invasion to adjacent structures and lymph node 
involvement. These tools are employed based on the area of interest.  
 The imaging tool used for diagnostic is contingent upon the location of the 
tumor. Due to its abilities to detect soft tissue subtleties, MRI is a preferred imaging 
tool for cancers of the nasopharynx, paranasal sinuses, salivary glands, and 
oropharynx. CT scans are preferred due to the associated cost and times for imaging 
and are used for bony protrusions such as the mandible, while PET scans are 
beneficial in determining extent of regional lymph node involvement (Brockstein, 
2003).  
 Molecular testing is used as means to identify specific genes, proteins, and 
molecular aspects of the tumor; this is beneficial in creating a personalized therapy 
approach to target the identified markers (Bernier, 2011).  
 
Treatment/standards of care: 
 
 A patients’ prognosis and treatment approach is highly contingent on the 
staging of the cancer when it is discovered as well as the location. Several therapies 
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are employed in treatment of head and neck cancers: radiation therapy, surgery, 
chemotherapy, and targeted therapy; often multiple modalities are used to ensure 
there will not be recurrence. (Brockstein, 2003).  
 Surgeries range from total removal of regions such as seen in tonsillectomies 
and laryngectomies, which target the primary tumor sites for successful resection. 
However, in the case of cancers that have metastasized with evidence of lymph 
node involvement, procedures such as neck dissections are performed in which 
lymph nodes and diseased vasculature are excised (Brockstein, 2003).  
 Early stage head and neck cancers, stage I and stage II, specifically, can be 
cured 60-95% of the time with surgery or radiation (Brockstein, 2003). Different 
modalities are employed as the standard of treatment depending on the region. 
Surgical intervention is favored, particularly in early stage cancers, however the 
resultant disfigurements must be taken into account as they could lead to difficulty 
with daily functions such as eating, swallowing, and speaking. This modality is also 
favored due to the issue with patient compliance that becomes relevant with 
continuous radiation therapy treatments in terms of compliance with treatment 
schedule, and post-treatment care. Other than nasopharyngeal cancers, surgical 
resection is the standard of treatment for the typical patient that presents with 
early stage HNC (Brockstein, 2003).  
 Advance stage cancers are curable in a meager 30-40% of reported cases, 
and unfortunately, two thirds of those diagnosed with HNC are diagnosed at 
advanced stages (Brockstein, 2003). Nonmetastatic stage IV HNC’s are deemed 
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curable in contrast to metastatic or recurrent advanced HNC. Patients with 
metastatic disease or locoregionally recurrent diseases are generally treated for 
palliation with concomitant chemotherapy and radiation therapy being the standard 
of care (Brockstein, 2003).  
 Treatment modalities, while largely based on the staging of the cancer at 
time of diagnosis, must consider the region. As aforementioned, head and neck 
cancers pose an additional complexity when assessing viable treatment options as 
vital functions such as breathing, speaking, and swallowing can be compromised. 
With cancers of the oral cavity, radiotherapy is not the recommended standard of 
treatment due to the proximity to the mandible and maxilla as it can result in 
osteoradionecrosis, death of the bone, of these structures, which could lead to 
further complications (Brockstein, 2003).  Laryngeal cancers pose the issue of 
speech quality after treatment; while voice quality is reported to be better long-
term when patients are treated with radiotherapy rather than surgery, chance of 
recurrence is greater (Brockstein, 2003).  
 
T4b – What defines resectability?  
 
 Stage 4 cancer defines the most aggressive stage of cancer, staged as such 
due to the size of the tumor, excessive nodal involvement, or distant metastasis. In 
2002, the American Joint Committee on Cancer (AJCC) redefined T4 and divided it 
into subgroups a and b. T4b is defined as the more aggressive form, having a poorer 
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prognosis and higher rate of unresectibility than T4a. This assignment is made 
based on imaging to evaluate the level of infiltration of the cancer. The criteria for 
T4b categorization is as follows: vascular encasement and invasion in surrounding 
vessels such as the carotid artery and jugular vein, prevertebral space invasion, 
specifically fixation of the tumor to prevertebral musculature, and mediastinal 
invasion, which refers to infiltration of the supra-aortic vessels, aortic arch, and 
mediastinal fat (Yousem, 2006). T4a is designated the moderately advanced cancer, 
and T4b the very advanced local disease. Head and neck cancers are difficult to 
assess as T4a versus T4b as resectibility is contingent upon many factors that are 
unique to each case.  
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METHODS  
 
 In seeking to compare the outcomes of patients with advanced stage head 
and neck cancers based on treatment modality (surgery and chemoradiation, 
chemoradiation, no treatment), medical records for patients diagnosed with head 
and neck cancer at Boston Medical Center between June 2009 and October 2011 
were screened. Of the 320 cases reviewed, 18 patients with stage IVb tumors were 
identified. These charts were reviewed up through October 2014 in order to 
determine three-year survival. From these records, date of initial diagnosis, 
diagnosis, treatment types and dates, and date of death were extrapolated. Mean 
survival rates were calculated to compare survival outcomes of those who received 
and those who did not receive surgical intervention by averaging the total number 
of months between diagnoses and death of patients in both groups. Survival curves 
were then created using graphing software GraphPad Prism, Version 6.0f by 
inputting the patient survival rates into a chart.  
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RESULTS 
 
 
 Upon the screening of patients diagnosed with head and neck cancer 
between June 2009 and October 2011, eighteen patients of the 320 cases were 
found to have stage IVb tumors. Of the 18 patients, 3 were female and 15 were 
males. While the number of patients included in this study is small, this distribution 
among males and females reflects the trends of head and neck cancer, as men 
reportedly have 3.5 times the incidence as women (Brockstein, 2003). The mean age 
of diagnoses was 56.61 with the youngest patient of twenty-eight years and the 
oldest seventy-four. The mean age for females at time of diagnosis was 54.67 years, 
and 57 years for the males. Cancer of the oral cavity and lips were most common in 
this cohort with 10 patients presenting with tumors in this region. Pharyngeal 
cancers were identified in 6 patients, 4 of which were in the oropharynx, and 2 in 
the nasopharynx, and the remaining two patients had cancers in the nasal cavity 
(paranasal sinus) and salivary glands (parotid gland).  Ten patients were identified 
as Caucasion, one Hispanic, one Asian, and two patients did not identify their race.  
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Table 1: Demographics of patients included in this study.  
 
N = 18 
Males = 15 
Females = 3 
Age Range = 28-74 
Mean Age at Dx = 56.61 
Caucasian: 10 
Black/African American: 4 
Asian: 1 
Hispanic: 1 
Race not Identified: 2 
Subsites: 
• Mandible (oral cavity): 1 
• Nasopharynx (pharynx): 2 
• Base of Tongue (pharynx): 4 
• Parotid Glands (salivary glands): 1 
• Oropharynx(pharynx): 4 
• Lip and Oral (oral cavity): 3 
• Hard Palate(oral cavity): 2 
• Paranasal Sinus (nasal cavity): 1 
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 Of the eighteen patients, 12 were treated with surgery followed by 
chemoradiation therapy, and 4 were treated with only chemoradiation therapy and 
2 opted out of treatment and were put in hospice care.  The types of surgeries 
performed included neck dissection, tracheostomy, alveoplasty, total laryngectomy, 
parotidectomy, tonsillectomy, multiple tooth extraction, sphenoidectomy, 
ethnoidectomy, and often many involved facial reconstruction and skin grafts. 
Tables 2  and 3 delineate the survival rates of the patients included in the study with 
and without surgical intervention respectively, while Table 3 provides comparison 
of survival rates based on stage, location, and treatment modality.   
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Table 2: Survival outcomes of patients with surgery:  
Patient # Date of Dx Date of 
Surgery 
Date of Death Survival 
(months) 
1 9/22/10 10/28/10 3/1/11 6 
2 5/10/11 6/24/11 3/26/12 10 
3 5/10/10 6/14/10 Living 51 
4 10/8/10 10/28/10 Living 46 
5 6/18/09 3/11/10 12/2010 18 
6 11/11/10 6/23/11 11/2/12 24 
7 10/8/10 12/2/10 Living 46 
8 2/11/11 11/8/12 Living 42 
9 12/10/10 3/4/11 5/1/12 17 
10 10/18/11 11/21/11 Living 33 
11 10/28/11 11/17/11 Living 33 
12 11/18/11 12/8/11 Living 33 
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Table 3: Survival outcomes of patients without surgical intervention 
Patient # Date of Dx Date of Rx 
(CRT) 
 Date of Death Survival 
(months)  
1 7/8/10 8/4/10 8/8/10 1 
2 3/24/11 4/26/11 6/13/2011 39 
3 3/14/11 None 4/20/11 1 
4 5/3/11 5/18/11 Living 39 
5 4/13/11 5/26/11 Living 40 
6 10/13/11 None 3/6/12 5 
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Table 4: Survival comparison based on treatment modality and location.  
Rx Modality Stage Location AJCC 5 yr 
survival 
Survival 
(months) 
CRT T4b, N3, M0 Pharynx 
(nasopharynx) 
38.4% 1 
CRT T4b, N2, M0 Pharynx 
(oropharynx) 
26.8% 39 
CRT T4, N2, M0 Pharynx (base 
of tongue) 
26.8% 39 
CRT T4b, N3, M0 Pharynx 
(nasopharynx) 
26.8% 40 
None T4b, N2, M0 Pharynx 
(oropharynx) 
32.4% 1 
None T4b, N0, M0 Oral Cavity (lip 
and oral) 
26.5% 5 
Surgery +CRT T4b, N1, MX Oral Cavity 
(mandible) 
25% 6 
Surgery +CRT T4, N1, M0 Pharynx (base 
of tongue) 
26.5% 10 
Surgery +CRT T4b, N0, M0 Salivary 
Glands 
(parotid) 
38.5 51 
Surgery +CRT T4a, N2, M0 Pharynx 
(oropharynx) 
32.4% 
 
46 
Surgery +CRT T4b, N2, M0 Pharynx (base 
of tongue) 
32.4 18 
 
Surgery +CRT T4b, N1, M0 Oral Cavity (lip 
and oral) 
26.5 24 
Surgery +CRT T4a, N0, M0 Oral Cavity 
(hard palate) 
32.4 46 
Surgery +CRT T4a, N2, M0 Pharynx 
(oropharynx) 
32.4 42 
Surgery +CRT T4b, N2, M0 Pharynx (base 
of tongue) 
26.5% 17 
Surgery +CRT T4b, N0, M0 Nasal cavity 
(paranasal 
sinus) 
29.2% 33 
Surgery +CRT T4b, N2, M0 Oral cavity 
(hard palate)  
40% 33 
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Surgery +CRT T4b, N2, M0 Oral cavity (lip 
and oral) 
26.5 33 
 Nine patients, (50% of the reviewed patients) were living at the last date of 
data collection (October 2014). Of these 9 patients, 7 had undergone surgical 
intervention while the remaining two only had chemoradiation. 58.3% of patients 
that had undergone surgery were still living at the time of collected data while 
33.33% of those that did not have surgery were living. It was found that the mean 
survival rate (in months) for patients who underwent surgery was 29.92 months, 
over 9 months longer than the mean survival rate of those who did not undergo 
surgery at 20.83 months after initial diagnosis. The average age at time of death was 
60.3 years, 51.25 years for those who did not receive surgical intervention, and 67.6 
years for those who underwent surgery.  
 
Table 5: Outcome Demographics: 
 
Patients living at end of collection date (October 2014): 9 
- Surgical treatment: 7 = 58.3% total group of patients that 
underwent surgery 
- Chemoradiation Therapy: 2 = 33.33% of patients that did not have 
surgery 
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Figure 6: Survival curve – comparison of survival after time of diagnoses between 
patients with and without surgical intervention.  
 
 Figure 6 displays a survival curve of patients evaluated in this study. The 
figure was created by inputting patient survival rates into the graphing software 
GraphPad Prism (Version 6.0f). The  resultant survival curve demonstrates the 
comparison between survival rates of those patients that underwent surgery and 
those who did not. As shown, there was a greater percentage of patients that 
survived beyond those who did not receive surgical intervention.  
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DISCUSSION 
 
 Standard treatment protocol advises against surgical intervention for T4b, 
advanced stage, head and neck cancers. The National Comprehensive Cancer 
Network (NCCN), an organization that develops practice guidelines for oncological 
care, delineates the standards of care and treatment protocols for all cancer 
subtypes. Course of treatment for advanced stage head and neck cancers mandate 
chemoradiation therapy as palliative treatment and advise against surgical 
intervention (see Figures 11-14). 
 
Figure 7: NCCN Treatment Guidelines Very Advanced Head and Neck Cancer – part 
1 (Figure downloaded from National Comprehensive Cancer Network at 
www.oralcancerfoundation.org).  
 
 32 
 
Figure 8: NCCN Treatment Guidelines Very Advanced Head and Neck Cancer – part 
2 (Figure downloaded from National Comprehensive Cancer Network at 
www.oralcancerfoundation.org).  
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Figure 9: NCCN Treatment Guidelines Very Advanced Head and Neck Cancer – part 
3 (Figure downloaded from National Comprehensive Cancer Network at 
www.oralcancerfoundation.org).  
 
Figure 10: Eastern Cooperative Oncology Group (ECOG) Performance Status Chart 
(Figure downloaded from National Palliative Care Research Center at 
www.npcrc.org).  
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 Performance status, or PS, is scaled 0-5 with 0 being the most capable and 
unrestricted in regards to performing daily activities, 1-4 rating increasing level of 
disability, and 5, deceased (see Figure 10).  As seen in Figuress 7, 8, and 9, NCCN 
protocol does not include surgical intervention for advanced stage, unresectable, 
otherwise known as T4b, head and neck cancers.  
 It is proposed that surgical intervention should not be disregarded as a viable 
option for patients with T4b head and neck cancers. In evaluating and comparing 
the outcomes and survival rates of patients treated with and without surgical 
intervention, the collected data suggests more favorable outcomes for those that 
underwent surgical intervention as the mean survival rate for those that had 
surgical intervention was 29.92 months; 9.09 months longer than those who did not 
undergo surgery as treatment with the groups mean survival rate being 20.82 
months. While median survival for late stage HNC is reported to be 6-9 months with 
a 20-30% one year survival rate, all twelve patients included in the study that 
underwent surgical treatment survived 6 months or longer, and ten of the twelve, 
83.33%, survived a year or longer (Brockstein, 2003).  
 Several studies conducted at Chang Gung Memorial Hospital in Taiwan 
demonstrated comparable resection outcomes of T4a and T4b oral cavity squamous 
cell carcinomas, leading to the recommendation that the studied tumors, resectable 
infra-notch T4b tumors, be reclassified as T4a in the AJCC tumor staging (Liao et al., 
2012). This finding suggests that T4b should not be deemed unresectable 
conclusively. Considering the evolving nature of medicine, we should not be 
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restricted to standard protocols. Guidelines are provided to direct physicians in 
their approaches to patient care, however they are not meant to be set rules; it 
should be recognized that no one tumor, patient, or circumstance is the same and 
treatments must be tailored to an individual. Existing literature supports this notion 
as surgeons attempt novel surgical techniques in order to achieve maximal resection 
of more aggressive cancers (Sabatini, 2009; Liao et al., 2006).  Studies are looking 
into further substaging within T4 cancers due to the fact that different stages have 
different prognoses’ – this effort suggests that T4b should not be looked at as an 
unresectable stage as each cancer is unique (Rivera et al., 2008). 
 An alternative staging method known as volumetric staging has been 
proposed which, unlike the TNM staging system that categorized with regards to 
size, node involvement, and level of metastases, evaluates tumors based on gross 
tumor volume. According to a study performed in the radiation oncology 
department of University Hospital of Zurich, volumetric staging proved to be a 
superior staging technique in terms of predicting outcome of patients with head and 
neck cancer (Studer & Glanzmann, 2013). With cancer staging and evaluation being 
such an important indicator of treatment options, the new methods of tumor 
evaluation suggest the TNM system is not a comprehensive staging tool and staging 
designation is not definitive.  
  There are several limitations and considerations that must be accounted for 
in this study. While survival rates were calculated by time of survival from date of 
initial diagnoses, some patients were diagnosed earlier than others analyzed in this 
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study, while the cut-off date for survival rate calculation was the same (October 
2014). This affects the data as patients’ survival rate differences may be attributable 
to the time of diagnoses, rather than the form of intervention. 
 The nature of the cancers of those patients that had not undergone surgical 
intervention must be taken into consideration; though a less favorable mean 
survival rate was demonstrated in this study, those patients may have had more 
aggressive and complex cancers that were truly inoperable. An additional 
consideration that must be accounted for is patient demographics. Those that 
forewent surgical intervention may have not had access to adequate healthcare 
resources due to social or economic factors, affecting their survival rates due to 
inadequate care, noncompliance with treatment regimens, and ability to afford 
treatments.  
 While the number of subjects limits this study, the purpose is to offer surgery 
a treatment option for patients of this aggressive-staged cancer. This proposal is not 
specific to any head and neck regions as several instances were evaluated in this 
study of patients with cancers of different sub sites and surgeries. T4b cancer is 
characterized as unresectable, but the data suggests that cases need to be evaluated 
with a case-by-case approach as surgical intervention may be a viable option for 
many with advanced stage head and neck cancer and may better their chances at 
longer-term survivals.  
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CONCLUSION 
  
  It is understandable for both physicians and patients to err on the side of 
caution when determining whether or not to move forward with surgery as a viable 
treatment option. As is the case with any surgical procedure, there are risks that 
must be considered; the operating surgeon and oncological team must work with 
the patient to determine the best treatment option. With head and neck cancers, risk 
of impairing functions vital for daily life such as breathing, speaking, and swallowing 
are imperative to consider, along with disfigurement; all factors contribute to a 
persons quality of life. The benefits must be weighed against the risks as in some 
cases, the difference in survival rate with versus without surgery may not be 
significant considering the possible complications and resultant outcomes.  
 While standard protocol advises against surgical intervention as means of 
treatment for advanced stage T4b head and neck cancers, the findings of this study 
suggest protocol be adjusted to consider surgery as a viable treatment option. 
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